Elicera Therapeutics AB (publ) (STO:ELIC)
Sweden · Delayed Price · Currency is SEK 2.730
+0.015 (0.55%)
Sep 22, 2026, 5:29 PM CET
Elicera Therapeutics AB Revenue
Elicera Therapeutics AB had revenue of -147.66K SEK in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 7.79M, up 29.45% year-over-year. In the year 2025, Elicera Therapeutics AB had annual revenue of 10.86M with 52.28% growth.
Revenue (ttm)
7.79M
Revenue Growth
+29.45%
P/S Ratio
23.38
Revenue / Employee
2.60M
Employees
3
Market Cap
182.19M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.86M | 3.73M | 52.28% |
| Dec 31, 2024 | 7.13M | -4.10M | -36.52% |
| Dec 31, 2023 | 11.23M | 9.95M | 777.23% |
| Dec 31, 2022 | 1.28M | 1.28M | 217,987.39% |
| Dec 31, 2021 | 587.00 | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 750.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sprint Bioscience AB | 139.36M |
| Xbrane Biopharma AB | 83.30M |
| IRLAB Therapeutics AB | 79.33M |
| NextCell Pharma AB | 10.78M |
| Abera Bioscience AB | 9.10M |
| Xintela AB | 3.03M |
| Simris Group AB (PUBL) | 1.39M |
| Diamyd Medical AB | 432.00K |
Elicera Therapeutics AB News
- 25 days ago - Elicera Therapeutics AB Quarterly report: Q2 2026 - Filings
- 5 months ago - Elicera Therapeutics AB Quarterly report: Q1 2026 - Filings
- 7 months ago - Elicera Therapeutics AB Quarterly report: Q4 2025 - Filings
- 7 months ago - Elicera Therapeutics AB Annual report: Q4 2025 - Filings
- 10 months ago - Elicera Therapeutics AB Quarterly report: Q3 2025 - Filings